Spruce Biosciences (SPRB) Stock Forecast & Price Target

Compare

450 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SPRB Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Spruce

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SPRB Stock 12 Month Forecast

Average Price Target

$217.67

▲(262.42% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Spruce Biosciences in the last 3 months. The average price target is $217.67 with a high forecast of $283.00 and a low forecast of $170.00. The average price target represents a 262.42% change from the last price of $60.06.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","74":"$74","144":"$144","214":"$214","284":"$284"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":283,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$283.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":217.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$217.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$170.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,74,144,214,284],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Aug<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.205,71.80461538461539,89.40423076923076,107.00384615384615,124.60346153846154,142.20307692307694,159.80269230769233,177.40230769230772,195.0019230769231,212.6015384615385,230.2011538461539,247.80076923076928,265.4003846153846,{"y":283,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.205,66.77923076923076,79.35346153846153,91.9276923076923,104.50192307692308,117.07615384615383,129.6503846153846,142.2246153846154,154.79884615384614,167.3730769230769,179.94730769230767,192.52153846153846,205.09576923076924,{"y":217.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.205,63.112307692307695,72.01961538461538,80.92692307692307,89.83423076923077,98.74153846153847,107.64884615384616,116.55615384615385,125.46346153846154,134.37076923076924,143.27807692307692,152.18538461538463,161.09269230769232,{"y":170,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34.76,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.12,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41.09,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":31.5,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.12,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.49,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.18,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.11,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.11,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.99,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.205,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$283.00

Average Price Target$217.67

Lowest Price Target$170.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jonathan Wolleben

Citizens JMP

$180→$170

Buy

183.05%

Upside

Reiterated

03/10/26

Spruce Biosciences price target lowered to $170 from $180 at CitizensSpruce Biosciences price target lowered to $170 from $180 at Citizens

Ram Selvaraju

H.C. Wainwright

$200

Buy

233.00%

Upside

Reiterated

03/10/26

Clear Regulatory Path and Strong Cash Position Underpin Buy Rating on Spruce Biosciences and Tralesinidase Alfa

Leland Gershell

Oppenheimer

$283

Buy

371.20%

Upside

Reiterated

03/10/26

Oppenheimer Remains a Buy on Spruce Biosciences (SPRB)

Joseph Schwartz

Leerink Partners

$160

Buy

166.40%

Upside

Upgraded

12/03/25

Spruce Biosciences upgraded to Outperform from Market Perform at LeerinkSpruce Biosciences upgraded to Outperform from Market Perform at Leerink

Gregory Renza

Truist Financial

$37.5

Hold

-37.56%

Downside

Reiterated

05/06/25

Analysts Conflicted on These Healthcare Names: Spruce Biosciences (Other OTC: SPRB), Cigna (NYSE: CI) and Axsome Therapeutics (NASDAQ: AXSM)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jonathan Wolleben

Citizens JMP

$180→$170

Buy

183.05%

Upside

Reiterated

03/10/26

Spruce Biosciences price target lowered to $170 from $180 at CitizensSpruce Biosciences price target lowered to $170 from $180 at Citizens

Ram Selvaraju

H.C. Wainwright

$200

Buy

233.00%

Upside

Reiterated

03/10/26

Clear Regulatory Path and Strong Cash Position Underpin Buy Rating on Spruce Biosciences and Tralesinidase Alfa

Leland Gershell

Oppenheimer

$283

Buy

371.20%

Upside

Reiterated

03/10/26

Oppenheimer Remains a Buy on Spruce Biosciences (SPRB)

Joseph Schwartz

Leerink Partners

$160

Buy

166.40%

Upside

Upgraded

12/03/25

Spruce Biosciences upgraded to Outperform from Market Perform at LeerinkSpruce Biosciences upgraded to Outperform from Market Perform at Leerink

Gregory Renza

Truist Financial

$37.5

Hold

-37.56%

Downside

Reiterated

05/06/25

Analysts Conflicted on These Healthcare Names: Spruce Biosciences (Other OTC: SPRB), Cigna (NYSE: CI) and Axsome Therapeutics (NASDAQ: AXSM)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Spruce Biosciences

3 Months

xxx

Success Rate

9/20 ratings generated profit

Average Return

+25.64%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 45.00% of your transactions generating a profit, with an average return of +25.64% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

2/20 ratings generated profit

Average Return

-35.12%

reiterated a buy rating 6 days ago

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -35.12% per trade.

2 Years

xxx

Success Rate

0/20 ratings generated profit

Average Return

-51.14%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -51.14% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SPRB Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SPRB has received 5 Buy Ratings, 25 Hold Ratings, and 4 Sell Ratings. SPRB average Analyst price target in the past 3 months is 217.67.

Each month's total comprises the sum of three months' worth of ratings.

SPRB Financial Forecast

SPRB Earnings Forecast

Next quarter’s earnings estimate for SPRB is -$8.81 with a range of -$15.21 to -$5.41. The previous quarter’s EPS was -$8.73. SPRB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year SPRB has Performed in-line its overall industry.

SPRB Sales Forecast

Next quarter’s sales forecast for SPRB is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SPRB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year SPRB has Performed in-line its overall industry.

SPRB Stock Forecast FAQ

What is SPRB’s average 12-month price target, according to analysts?

Based on analyst ratings, Spruce Biosciences’s 12-month average price target is 217.67.

What is SPRB’s upside potential, based on the analysts’ average price target?

Spruce Biosciences has 262.42% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SPRB a Buy, Sell or Hold?

Spruce Biosciences has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Spruce Biosciences’s price target?

The average price target for Spruce Biosciences is 217.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $283.00 ,the lowest forecast is $170.00. The average price target represents 262.42% Increase from the current price of $60.06.

What do analysts say about Spruce Biosciences?

Spruce Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of SPRB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Spruce Biosciences (SPRB) Stock Forecast & Price Target

SPRB Analyst Ratings

SPRB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Spruce Biosciences

SPRB Analyst Recommendation Trends

SPRB Financial Forecast

SPRB Earnings Forecast

SPRB Sales Forecast

SPRB Stock Forecast FAQ

Detailed List of Analyst Forecasts